IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

Journal of Hematology & Oncology

Gregory N. Gan¹  Chengliang Huang²  Jun Zhang³ 

[1] Department of Radiation Oncology, University of Kansas Cancer Center, University of Kansas Medical Center;Department of Respiratory and Critical Care Medicine II, The Affiliated Hospital of Southwest Medical University;Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, University of Kansas Medical Center;

关键词: Extensive-stage small cell lung cancer;    Immunotherapy;    PD-1;    PD-L1;    Radiation therapy;    CTLA-4;   

DOI  :  10.1186/s13045-020-00898-y

来源: DOAJ

【 摘 要 】

Abstract The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2–3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone. However, such benefit is relatively small and was not even observed in some other trials using immunotherapy, raising the question of optimal chemoimmunotherapy combination in the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking questions with the focus on IMpower133 and CASPIAN trials.

【 授权许可】

Unknown